Xu Xiao-Feng, Wei Zhi-Feng, Zhang Zheng-Yu
Department of Urology, Nanjing General Hospital of Nanjing Military Region, Nanjing, Jiangsu 210002, China.
Zhonghua Nan Ke Xue. 2017 Jan;23(1):78-81.
Over 80% of the patients with prostate cancer (PCa) develop bone metastasis, which seriously affects the patients' quality of life and remains a major cause of morbidity. Radium-223 (Ra-223), a newly approved agent targeting bone metastasis of PCa, can improve the quality of life and prolong the overall survival of the PCa patients with bone metastasis. This article presents an overview of the clinical trials recently published on the management of bone metastasis of PCa with Ra-223.
超过80%的前列腺癌（PCa）患者会发生骨转移，这严重影响患者的生活质量，并且仍然是发病的主要原因。镭-223（Ra-223）是一种新批准的针对PCa骨转移的药物，可改善PCa骨转移患者的生活质量并延长其总生存期。本文概述了最近发表的关于用Ra-223治疗PCa骨转移的临床试验。
